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Abstract 
Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, 
associated with the production of a monoclonal immunoglobulin (M protein) which can be detected 
in the blood and/or urine. Multiple lines of evidence suggest that genetic factors are involved in MM 
pathogenesis, and several studies have identified single nucleotide polymorphisms (SNPs) associated 
with the susceptibility to the disease. SNPs within miRNA-binding sites in target genes (miRSNPs) 
may alter the strength of miRNA–mRNA interactions, thus deregulating protein expression. 
MiRSNPs are known to be associated with risk of various types of cancer, but they have never been 
investigated in MM. We performed an in silico genome-wide search for miRSNPs predicted to alter 
binding of miRNAs to their target sequences.  We selected 12 miRSNPs and tested their association 
with MM risk. Our study population consisted of 1,832 controls and 2,894 MM cases recruited from 
7 European countries and Israel in the context of the IMMEnSE (International Multiple Myeloma 
rESEarch) consortium. In this population two SNPs showed an association with p<0.05: rs286595 
(located in gene MRLP22) and rs14191881 (located in gene TCF19). Results from IMMEnSE were 
meta-analyzed with data from a previously published genome-wide association study (GWAS). The 
SNPs rs13409 (located in the 3’UTR of the POU5F1 gene), rs1419881 (TCF19), rs1049633, 
rs1049623 (both in DDR1) showed significant associations with MM risk. In conclusion, we sought 
to identify genetic polymorphisms associated with MM risk starting from genome-wide prediction of 
miRSNPs. For some mirSNPs we have shown promising associations with MM risk. 
 
What's new? Even though deregulation of miRNA expression has been associated with human 
cancers little information is available regarding their relation with MM susceptibility. We performed 
an in silico genome-wide search for miRSNPs and selected the most promising ones for an association 
study. The SNPs with the strongest associations with MM risk are localized in genes which have 
never been related with MM.  
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Introduction 
Multiple myeloma (MM) is a malignancy of plasma cells, usually infiltrating the bone marrow, 
and associated with the production of a monoclonal immunoglobulin (M protein) which can be 
detected in the blood and/or urine. MM affects the places where bone marrow is normally active in 
an adult. MM is a relatively infrequent cancer among both sexes. On a worldwide scale, it is estimated 
that about 86,000 incident cases occur annually, accounting for about 0.8% of all new cancer cases. 
About 63,000 subjects are reported to die from the disease each year, accounting for 0.9% of all 
cancer deaths and nearly 10% of all haematological neoplastic diseases. 
Several factors are known or suspected to cause myeloma or trigger an already abnormal or 
damaged pre-myeloma cell population in the bone marrow. Exposure to toxic chemicals, ionizing 
radiations, immunodeficiency, or infection with cancer-causing viruses have all been implicated as 
causes or triggers of MM1. Converging evidence of MM in monozygotic twins and familial 
aggregation of MM strongly suggest that MM aetiology has a robust genetic component as well2. 
Several risk loci have been proposed and a few have been identiﬁed through candidate gene and 
genome-wide association studies (GWAS)3–10.  Some of these loci are involved in complex pathways 
related to cell cycle, cell proliferation and DNA repair, in which micro-RNAs (miRNAs) have a 
proven regulatory role11.  
MiRNAs are small non-coding RNA molecules, 20-25 nucleotides long, highly conserved 
throughout evolution. In mammals, miRNAs are predicted to control the activity of more than 60% 
of all protein-coding genes and participate in the regulation of almost every cellular process 
investigated to date12. They play a major role in post-transcriptional regulation processes, mainly 
silencing target mRNAs and thus decreasing their corresponding protein expression13.  
These small RNAs post-transcriptionally repress gene expression by recognizing complementary 
target sites most often in the 3' untranslated region (UTR) of target messenger RNAs (mRNAs). 
Several miRNAs were found to be directly involved in human cancers, including lung, breast, brain, 
liver, colon cancer and leukemia. In addition, some miRNAs may function as oncogenes or tumor 
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suppressors in tumor development. Furthermore, a widespread down-regulation of miRNAs is 
commonly observed in human cancers, which promotes cellular transformation and tumorigenesis14–
17.  Recent studies have revealed a role of miRNAs in MM. Deregulated miRNA expression in plasma 
cells has been associated with tumor progression, molecular subtypes, clinical staging, prognosis, and 
drug response in MM18. 
Although mutation in miRNA seed sequence seems to be a rare event, sequence variation in 
miRNA target sites is relatively frequent and may play a role in cancer etiology. In silico analyses of 
expressed sequence tag SNP databases indicate different allele frequencies of miRNA-binding sites 
in tumors versus normal tissues19. Polymorphisms in miRNA-binding sites in target genes may alter 
the strength of miRNA–mRNA interactions, thus deregulating protein expression. SNPs belonging to 
this category are called miRSNPs20. MiRSNPs have been shown to be associated with the risk of 
several cancers 21–23  . 
We hypothesize that miRSNPs may have a role in the susceptibility of MM. To this aim, we 
performed an in silico genome-wide search of miRSNPs predicted to affect binding of micro-RNAs 
to their target genes and tested the most promising ones in a case-control association study.  
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Materials and methods 
Study population 
The study population consisted of 1,832 controls and 2,894 MM cases recruited from 7 European 
countries and Israel in the context of the IMMEnSE (International Multiple Myeloma rESEarch) 
consortium (table 1)24 . 
Diagnosis of patients with symptomatic MM was carried out by haematologists according to the 
International Myeloma Working Group (IMWG) criteria. Demographic and clinicopathological 
characteristics including age, gender, country of origin, disease stage (Durie-Salmon and/or 
International Staging System) and serum creatinine levels were retrospectively gathered from medical 
records in each participant institution. 
Controls were selected among the general population (Italian), blood donors (Danish, Spanish, 
Polish, Portuguese and French), and hospitalized subjects with different diagnoses excluding cancer 
(Hungarian, Spanish). Gender and age at recruitment were collected for every subject enrolled. Cases 
and controls are not matched individually but age distribution and sex ratio were similar between 
cases and controls (table 1). Control samples have been collected in the same centers of the cases, or 
at least in the same geographic areas. 
In keeping with the guidelines of the Declaration of Helsinki, written informed consent was 
obtained from each participant and approval for collection and use of the samples was obtained from 
local Institutional Review Boards. 
 
SNP selection criteria  
 A search for mirSNPs was carried out on the whole genome. Polymorphisms were selected using 
bioinformatic tools and consultation of results of a previously published GWAS on MM risk. The 
selection of miRSNPs was conducted with the following criteria (Figure 1): 
 location in 3’UTR of known genes 
 high conservation score, ≥ +1 
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 MAF (minor allele frequency ) ≥ 0.05 in Caucasians 
 the strength of binding between each miRNA and its target sequence with the major and the 
minor allele (measured in silico), using mrSNP 25 
 location in genes that are expressed in MM cells, using Oncomine 26 
 
Putative miRNA-binding sites within the 3’UTR (defined as transcribed sequences from the stop 
codon to the end of the last exon of each gene) were detected by jSNPSelector version 1.0.1.7 
(http://sourceforge.net/projects/jsnpselector/), a custom-made algorithm that interrogates the 
ENSEMBL database. The conservation score is assigned to each nucleotide in a multiple species 
alignment to determine how conserved the nucleotide is. 
The strength of binding with the major and the minor allele was measured in silico using the 
publicly available mrSNP software (http://mrsnp.osu.edu). mrSNP showed a good performance to 
predict SNPs experimentally validated to affect miRNA binding, correctly identifying 69% (11/16) 
of the SNPs disrupting binding25.  
The selection with the mentioned workflow resulted in a list of 394 SNPs with high difference 
in Gibbs free energy between the two alleles (ΔΔG) (Supplementary table 1). For mirSNPs predicted 
to bind more than one miRNA, we summed up all the ΔΔGs for each miRNA, obtaining thus a total 
ΔΔG.  
As a final step, we verified if these miRSNPs were associated with MM risk in a previously 
published GWAS data set4,6.  
 Based on the process described above, we started from 2,817 SNPs, and we finally selected 12 
SNPs reported in table 2. The final list included 3 SNPs (rs1050239, rs735794 and rs1052536) with 
highest predicted difference between the two alleles in the strength of binding between miRNAs and 
their target sequence (total ΔΔG), regardless of association in the previously performed GWAS, with 
a threshold of total ΔΔG>550 (another SNP, rs13505, had ΔΔG>550 as shown in supplementary table 
1, but it could not be designed as TaqMan assay and was therefore excluded). Three more SNPs 
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(rs1803275, rs12509103, rs3197716) had both a high total ΔΔG (ΔΔG>300) and p<0.05 for 
association with MM risk in the GWAS. The other 6 SNPs were selected according to the GWAS p-
value criterion, regardless of total ΔΔG, with an arbitrary threshold of p<0.005. 
 
SNP genotyping, quality control and data filtering 
Genomic DNA was extracted from peripheral blood or whole blood of MM cases and controls, 
using QIAampR 96 DNA QIAcubeR HT Kit. A whole genome amplification was carried out on 
samples with low levels of DNA. All the genotyping assays were carried out in 384-well format, with 
10 ng of DNA from each subject. The order of DNAs from cases and controls was randomized on 
plates in order to ensure that an equal number of cases and controls was analyzed simultaneously. For 
quality control purpose, duplicates of 10% of the samples were interspersed throughout the plates. 
Genotyping of the 12 selected miRSNPs was carried out by using the TaqMan Real Time PCR 
method. The quality of the genotype data was assessed on the basis of sample call rates (we accepted 
samples with at least 8 out of 12 SNPs successfully genotyped), concordance rates between duplicate 
DNAs (≥99%) and test for Hardy-Weinberg Equilibrium (HWE) among controls in each population. 
We applied a Bonferroni correction for multiple testing to calculate the significance threshold for 
HWE: 0.05/(12 SNPs x 8 countries) = 5.2x10-4.  
 
Statistical analysis  
Analysis of association between SNPs and MM risk was performed with multivariate logistic 
regression models, adjusting for a set of covariates including age (at diagnosis for MM cases, at 
recruitment for controls), gender and country of origin. The association between miRSNPs and MM 
risk was calculated by estimating odds ratios (OR) and their 95% confidence intervals (C.I.). For all 
genotypes, we performed a statistical analysis with the allelic, dominant, codominant and recessive 
models. Since 3 of our SNPs (rs1049633, rs1049628, rs1049623) were located in the same gene 
DDR1 (r2 ranging from 0.377 to 0.237 in Caucasians) and two more SNPs (rs1419881 and rs13409) 
 11 
are physically close to each other (r2=0.887), we calculated also MEFF correction. MEFF  is a simple 
correction for multiple testing of SNPs in linkage disequilibrium (LD) with each other, based on the 
spectral decomposition of matrices of pairwise LD between SNPs27. This method provides a useful 
alternative to more computationally intensive permutation tests. For performing this correction we 
used an interface available online (http://gump.qimr.edu.au/general/daleN/SNPSpD). We found a 
MEFF = 11.50. 
A P-value below 0.001, calculated with the formula 0.05/(11.5x4) was considered as threshold 
of statistical significance, considering the Bonferroni correction for MEFF and the number of 
inheritance models tested. 
Finally, we performed a meta-analysis between the data obtained in IMMEnSE and the data from 
two GWAS, respectively conducted in German and English populations4,6 . We considered the 
different countries participating in IMMEnSE and in the GWAS as separate groups and carried out 
meta-analyses according to the fixed effects model. 
All the statistical analyses were carried out using STATA software, version 11 for Windows.  
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Results  
IMMeNSE. As showed in table 3, we did not find strong associations between SNPs and MM 
risk. Table 3 reports the results of the analyses performed according to an allelic and codominant 
inheritance model. Two SNPs showed a p-value < 0.05: rs286595 (located in gene MRLP22) and 
rs14191881 (located in gene TCF19). Analyses of recessive and dominant models did not show any 
association at the level of 0.05 or below (data not shown). For all the analyses none of the SNPs 
passed the threshold of significance after correction for multiple testing. 
Meta-analysis. We performed a meta-analysis between the results from IMMEnSE and the 
published data of two GWASs conducted in the English and the German populations, respectively, 
for a total of 1,675 MM cases and 5,903 controls. Complete results are shown in supplementary table 
2. We found p-values <10-3 for the SNPs rs13409, rs1049623, rs1049633 and rs1419881 according 
to allelic or co-dominant model and no or minor heterogeneity, suggesting an association with a 
decreased risk of MM (table 4).  
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Discussion and conclusion  
The first steps of our study were the selection of the SNPs and the genotyping of cases and 
controls in the context of the IMMEnSE consortium. Although the sample size was adequate, none 
of the statistical analyses passed the significance threshold after the correction for multiple testing. 
However SNPs rs286595 (MRPL22) and rs14191881 (TCF19) showed a p-value < 0.05. The latter 
came up also in the meta-analysis, as did the SNPs rs1049633, rs1049623 (both located in the 3’UTR 
of the DDR1) and rs13409 (POU1F5), which all showed an association with a decreased risk of MM, 
with no heterogeneity between IMMEnSE and the GWAS except for one case (rs1049633, 
pheterogeneity=0.038).  
The protein encoded by the gene DDR1 belongs to a subfamily of tyrosine kinase receptors that 
are activated by various types of collagen. Upregulation of DDR1 in multiple human cancers implies 
that DDR1 is involved in tumor progression 28–30. Four different miRNAs are predicted to bind DDR1 
at the location of rs1049633: miR-2355-3p, miR-7, miR-3915, miR-4689. When A substitutes G, 
miR-2355-3p and miR-4689 are predicted to bind more tightly to the DDR1 3’UTR, instead, for miR-
7 and miR-3915 the A allele is predicted to decrease its binding affinity. MicroRNA-7 (miR-7) acts 
as a potential tumor suppressor, but the opposite effect also has been reported31. MiR-7 regulates 
diverse fundamental biological processes of cancer cells including initiation, proliferation, migration, 
invasion, survival and death by targeting a number of oncogenic signaling pathways. Two miRNAs 
are predicted to bind the DDR1 gene where the SNP rs1049623 is located: miR-4499 and miR-4513. 
We found out that carriers of C allele show a decreased risk of MM. The binding force of miRNAs 
for this SNP is predicted to be stronger when this allele is present, therefore it may be that when a C 
is present DDR1 is down-regulated, whereas usually this gene is up-regulated in cancer 32. Thus, the 
association we observed is consistent with the known biological function of DDR1. 
SNP rs1419881 is located in the gene TCF19 (transcription factor 19), which encodes a protein 
containing a PHD-type zinc finger domain and likely functions as a transcription factor. TCF19 was 
found to be involved in cell cycle progression and proliferation in the pancreatic β-cell and it plays a 
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role in the pathogenesis of diabetes33. Type 2 diabetes has been frequently associated with MM and 
it is thought to influence the myelomagenesis through hyperglycaemia and insulin-dependent and -
independent mechanisms34. Moreover, rs1419881 is in linkage disequilibrium (r2=0.82) with the SNP 
rs3130453 which is located in the gene CCHCR, also known as HCR (Supplementary table 2). The 
detailed function of the gene is still largely unknown. In particular, rs3130453 creates either a codon 
for tryptophan (G) or a stop codon (A). The stop codon (allele Iso3) results in the shorter isoform 
whereas the codon for tryptophan enables the usage of an earlier translation start site in exon 1b, thus 
leading to a protein with 89 additional amino acids in its N-terminal domain35. The most significant 
association in our analyses was found in the codominant model (p = 0.0002), where carriers of AA 
genotype have a decreased risk of MM.  
The gene POU5F1, where rs13409 is located, encodes a transcription factor containing a POU 
homeodomain that plays a key role in embryonic development and stem cell pluripotency. 
Interestingly, POU5F1 is also named as OCT-4 and it is one of the four main factors involved in the 
formation of the induced pluripotent stem cells36. It has a pivotal role in the maintenance of the 
differentiation status of, in practice, all types of cells and its regulation could be very important also 
for maintaining the appropriate differential state in B lymphocytes. 
This study has several strengths: large sample size and systematic, genome-wide search for 
miRSNPs. The genome-wide approach ensures that the whole set of common miRSNPs has been 
considered for this study. We cannot exclude that rarer miRSNPs have a role in MM risk, but a much 
larger sample size would be needed to address this issue. 
Predictions of miRNA-mRNA binding were carried out only with in silico tools and not 
experimentally confirmed. This could be a weakness of the study. Moreover, the vast majority of 
study subjects were Caucasians, thus it is not clear if these results can be generalized to other 
populations as well. Finally, the associations were largely driven by the German component of the 
GWAS results, and were weaker in IMMEnSE and in the English GWAS. Indeed, when the German 
population is excluded from the meta-analysis none of the SNPs were significant associated with MM 
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risk considering a Bonferroni-corrected threshold, although rs286595 was associated with p<0.05 
(supplementary table 3). Thus, the results of the meta-analysis should be taken with caution. 
However, we did not observe statistically significant heterogeneity among the IMMEnSE subgroups 
and the GWAS populations (except for rs1049633, pheterogeneity=0.038). 
In conclusion, we found promising associations between mirSNPs in DDR1, TCF19, POU5F1 
and MM risk, which should be further replicated in independent studies. If these associations are 
confirmed, it would be interesting to test the function of the SNPs with in vitro and in vivo studies.  
 
Conflicts of interest. Vibeke Andersen received compensation as a member of an advisory board 
(Merck/MSD) and as a consultant (Merck/MSD and Janssen). Hartmut Goldschimidt has potential 
conflicts of interest as follow: Research support (Celgene, Janssen, Chugai, Novartis, BMS, 
Millenium, Morphosys), Advisory Boards (Janssen, Celgene, Novartis, Onyx, Amgen Takeda, BMS), 
Speakers Bureau (Celgene, Janssen, Novartis, Chugai, Onyx, Millenium). Jan Zaucha received a 
travel grant from Celgene. 
 
 
  
 16 
References  
1.  Gold LS, Milliken K, Stewart P, Purdue M, Severson R, Seixas N, Blair A, Davis S, Hartge P, 
De Roos AJ. Occupation and multiple myeloma: an occupation and industry analysis. Am J 
Ind Med 2010;53:768–79.  
2.  Kristinsson SY, Björkholm M, Goldin LR, Blimark C, Mellqvist U-H, Wahlin A, Turesson I, 
Landgren O. Patterns of hematologic malignancies and solid tumors among 37,838 first-
degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 
2009;125:2147–50.  
3.  Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, 
Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, 
Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. 
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and 
multiple myeloma risk: a case-control study in the context of the International Multiple 
Myeloma rESEarch (IMMEnSE) consortium. Leukemia 2012;26:1419–22.  
4.  Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, Lloyd A, Olver B, Ma YP, Dobbins 
SE, Walker BA, Davies FE, Gregory WA, Child JA, Ross FM, Jackson GH, Neben K, Jauch 
A, Hoffmann P, Mühleisen TW, Nöthen MM, Moebus S, Tomlinson IP, Goldschmidt H, 
Hemminki K, Morgan GJ, Houlston RS. Common variation at 3p22.1 and 7p15.3 influences 
multiple myeloma risk. Nat Genet 2012;44:58–61.  
5.  Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, 
Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, 
Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, 
Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. The CCND1 c.870G>A 
polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 
2013;45:522–5.  
6.  Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, 
Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson 
GH, Irving JA, Pratt G, Fegan C, Fenton JAL, Neben K, Hoffmann P, Nöthen MM, Mühleisen 
TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan 
GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 
17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 2013;45:1221–5.  
7.  Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, García-
Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, 
Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, 
Landi S, Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and 
multiple myeloma risk in the IMMEnSE consortium. Br J Haematol 2012;157:331–8.  
8.  Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, 
Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, 
Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stępień A, Wątek M, 
Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SEH, Goldschmidt H, Sainz J, 
Hillengass J, Orciuolo E, Dudziński M, Weinhold N, Reis RM, Canzian F. Risk of multiple 
myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J 
Cancer J Int Cancer 2015;136:E351–8.  
9.  Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson B-
 17 
M, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, 
Lenhoff S, Masson G, Mellqvist U-H, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, 
Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, Nahi H, Gudbjartsson DF, Rafnar T, 
Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B. Variants in 
ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun 
2015;6:7213.  
10.  Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, 
Chen B, Halvarsson B-M, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, 
Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, 
Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist U-H, 
Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho 
MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, 
Wihlborg A-K, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, 
Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston 
RS. Genome-wide association study identifies multiple susceptibility loci for multiple 
myeloma. Nat Commun 2016;7:12050.  
11.  Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, Lynch HT, Hemminki K, 
Houlston RS. Inherited genetic susceptibility to multiple myeloma. Leukemia 2014;28:518–24.  
12.  Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 
2001;294:862–4.  
13.  Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–
97.  
14.  Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 
2011;585:2087–99.  
15.  Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C. Analysis of microRNA-target 
interactions across diverse cancer types. Nat Struct Mol Biol 2013;20:1325–32.  
16.  Chen X, Lu P, Wu Y, Wang D-D, Zhou S, Yang S-J, Shen H-Y, Zhang X-H, Zhao J-H, Tang J-
H. MiRNAs-mediated cisplatin resistance in breast cancer. Tumour Biol J Int Soc 
Oncodevelopmental Biol Med 2016; 
17.  Tagscherer KE, Fassl A, Sinkovic T, Richter J, Schecher S, Macher-Goeppinger S, Roth W. 
MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen. 
Cancer Cell Int 2016;16:42.  
18.  Bi C, Chng WJ. MicroRNA: important player in the pathobiology of multiple myeloma. 
BioMed Res Int 2014;2014:521586.  
19.  Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in 
cancer management and research. Pharmacogenomics Pers Med 2014;7:173–91.  
20.  Dzikiewicz-Krawczyk A. MicroRNA polymorphisms as markers of risk, prognosis and 
treatment response in hematological malignancies. Crit Rev Oncol Hematol 2015;93:1–17.  
21.  Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy 
M, Vodickova L, Gemignani F, Buchler T, Landi S, Vodicka P, Pardini B. Double-strand break 
repair and colorectal cancer: gene variants within 3’ UTRs and microRNAs binding as 
modulators of cancer risk and clinical outcome. Oncotarget 2015; 
 18 
22.  Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in 
cancer management and research. Pharmacogenomics Pers Med 2014;7:173–91.  
23.  Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian 
F, Novotny J, Barale R, Landi S. Identification of candidate genes carrying polymorphisms 
associated with the risk of colorectal cancer by analyzing the colorectal mutome and 
microRNAome. Cancer 2012;118:4670–80.  
24.  Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R, 
Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S, 
Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Genetics and molecular 
epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J 
Oncol 2012;40:625–38.  
25.  Deveci M, Catalyürek UV, Toland AE. mrSNP: software to detect SNP effects on microRNA 
binding. BMC Bioinformatics 2014;15:73.  
26.  Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, 
Chinnaiyan AM. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining 
Platform. Neoplasia N Y N 2004;6:1–6.  
27.  Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in 
linkage disequilibrium with each other. Am J Hum Genet 2004;74:765–9.  
28.  Kim H-G, Hwang S-Y, Aaronson SA, Mandinova A, Lee SW. DDR1 receptor tyrosine kinase 
promotes prosurvival pathway through Notch1 activation. J Biol Chem 2011;286:17672–81.  
29.  Cader FZ, Vockerodt M, Bose S, Nagy E, Brundler M-A, Kearns P, Murray PG. The EBV 
oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated 
activation of DDR1. Blood 2013;122:4237–45.  
30.  Valencia K, Ormazábal C, Zandueta C, Luis-Ravelo D, Antón I, Pajares MJ, Agorreta J, 
Montuenga LM, Martínez-Canarias S, Leitinger B, Lecanda F. Inhibition of collagen receptor 
discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung 
cancer bone metastasis. Clin Cancer Res Off J Am Assoc Cancer Res 2012;18:969–80.  
31.  Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, Lai Y, Li X. 
Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol 2013;44:669–77.  
32.  Roig B, Virgos C, Franco N, Martorell L, Valero J, Costas J, Carracedo A, Labad A, Vilella E. 
The discoidin domain receptor 1 as a novel susceptibility gene for schizophrenia. Mol 
Psychiatry 2007;12:833–41.  
33.  Krautkramer KA, Linnemann AK, Fontaine DA, Whillock AL, Harris TW, Schleis GJ, 
Truchan NA, Marty-Santos L, Lavine JA, Cleaver O, Kimple ME, Davis DB. Tcf19 is a novel 
islet factor necessary for proliferation and survival in the INS-1 β-cell line. Am J Physiol 
Endocrinol Metab 2013;305:E600–10.  
34.  Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi 
J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, 
Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, 
Orciuolo E, Jacobsen SEH, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz 
J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results 
from the IMMEnSE consortium. Endocr Relat Cancer 2015;22:545–59.  
 19 
35.  Tervaniemi MH, Siitonen HA, Söderhäll C, Minhas G, Vuola J, Tiala I, Sormunen R, 
Samuelsson L, Suomela S, Kere J, Elomaa O. Centrosomal Localization of the Psoriasis 
Candidate Gene Product, CCHCR1 , Supports a Role in Cytoskeletal Organization. PLOS 
ONE 2012;7:e49920.  
36.  Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to 
pluripotency. Nat Rev Mol Cell Biol 2016;17:183–93.  
 
  
 20 
Table 1. Description of the study population 
      
 Cases Controls Total 
Geographic origin 
Denmark 299 489 788 
France 360 176 536 
Hungary 155 101 256 
Israel 93 97 190 
Italy 298 228 526 
Poland 1,254 227 1.481 
Portugal 152 195 347 
Spain 283 319 602 
Total 2,894 1,832 4,726 
Median age (25–75% 
percentiles) 
62 (55–68)  53 (42–65)  
Gender 
Males    1,378 991 2,414 
Females 1,302  841 2,159 
    
 
      
  
 21 
 
Table 2. List of the selected SNPs 
 
miRSNP Gene Alleles Chromosome 
position 
Total 
ΔΔG 
p values 
(GWAS) 
Regulomea 
rs735794 SH3BP2 G>C 4:2,837,711 604.1 0.61608 2b: TF binding + any 
motif + DNase 
Footprint + DNase peak 
rs12509103 MFAP3L A>T 4:169,986,644 315.4 0.016448 3a: TF binding + any 
motif + DNase peak 
rs286595 MRPL22 C>T 5:154,968,992 171.3 0.0034897 3a: TF binding + any 
motif + DNase peak 
rs1049623 DDR1 T>C 6:30,897,052 53.4 0.00014557 5: TF binding or DNase peak 
rs1049633 DDR1 G>A 6:30,898,750 132.4 0.0017839 1f: eQTL + TF binding/DNase 
peak 
rs1049628 DDR1 C>T 6:30,899,329 182.2 0.0050759 5: TF binding or DNase peak 
rs1419881 TCF19 G>A 6:31,162,816 340.3 0.00094442 1f: eQTL + TF binding/DNase 
peak 
rs13409 POU5F1 G>A 6:31,164,363 164.1 0.0009308 4: TF binding + DNase peak 
rs1050239 SMPD1 G>A 11:6,394,233 638.6 0.74808 5. TF binding or DNase peak 
rs11628336 DCH24 G>A 14:23,043,713 301.6 0.028482 No Data 
rs1803275 IL16 G>A 15:81,306,075 338.2 0.02965 1f: eQTL + TF binding/DNase 
peak 
rs1052536 LIG3 C>T 17:35,004,556 550.1 0.52649 1f: eQTL + TF binding/DNase 
peak 
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Table 3. Results of the case/control study in IMMeNSE 
     Casesb Controlsb Allelic model Codominant model 
SNP Gene Alleles 
(M/m)a 
MM Mm Mm MM Mm mm ORc 95% CIc p ORhetc 95% CI p ORhomc 95% CI p 
rs735794 SH3BP2 G/C 1431 1206 302 848 771 177 0.99 0.88–1.10 0.79 0.88 0.75–1.02 0.09 1.1 0.85–1.40 0.45 
rs12509103 MFAP3L A/T 2412 483 6 1484 278 1 1.04 0.86–1.27 0.64 1.04 0.85–1.27 0.69 1.72 0.15–18.8 0.66 
rs286595 MRPL22 C/T 799 1471 640 538 857 357 1.12 1.01–1.24 0.03 1.14 0.95–1.34 0.14 1.25 1.01–1.54 0.03 
rs1049623 DDR1 T/C 417 1333 1185 711 841 228 1.08 0.96–1.19 0.18 0.91 0.73–1.14 0.43 1.08 0.85–1.36 0.51 
rs1049633 DDR1 G/A 2465 409 3 1498 276 6 0.82 0.67–1.00 0.05 0.85 0.66–1.01 0.07 0.49 0.10–2.36 0.38 
rs1049628 DDR1 C/T 1781 932 139 1077 594 67 1.01 0.88–1.14 0.93 0.93 0.80–1.09 0.38 1.24 0.87–1.78 0.24 
rs1419881 TCF19 G/A 1124 1278 439 594 873 288 0.98 0.88–1.09 0.75 0.82 0.70–0.97 0.02 1.05 0.84–1.30 0.66 
rs13409 POU5F1 G/A 1194 1304 418 666 864 265 1.02 0.92–1.13 0.68 0.91 0.77–1.06 0.22 1.12 0.89–1.39 0.31 
rs1050239 SMPD1 G/A 1872 902 133 1069 593 93 0.92 0.81–1.04 0.22 0.92 0.78–1.07 0.29 0.89 0.62–1.22 0.42 
rs11628336 DCH24 G/A 1025 1375 533 646 853 293 0.99 0.89–1.10 0.91 0.96 0.82–1.24 0.63 1 0.81–1.24 0.98 
rs1803275 IL16 G/A 2567 379 21 1528 259 11 0.98 0.81–1.19 0.9 0.95 0.77–1.17 0.66 1.42 0.55–3.64 0.47 
rs1052536 LIG3 C/T 878 1402 654 590 825 365 1.01 0.90–1.11 0.89 1.05 0.89–1.24 0.57 1 0.81–1.23 0.96 
 
    a    M = major allele (i.e., more common in controls); m = minor allele (less common in controls). 
    b    Numbers may not add up to 100% due to genotyping failure, DNA depletion or covariate missing values. 
    c    OR: odds ratio; CI: confidence interval; ORhet: odds ratio obtained comparing heterozygotes with homozygotes for the major allele; ORhom: odds ratio obtained comparing 
homozygotes for the minor allele with homozygotes for the major allele; all analyses were adjusted by age, sex and country of origin. Values in bold are statistically significant 
(p>0.05). 
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Table 4. Results of the meta-analysis for the allelic and codominant model 
 
SNP Gene Model OR 95% CI p p_heterogeneity 
rs13409 POUF51 Allelic 0.92 0.872-0.964 6.50 × 10−4 0.079 
    Codominant 0.85 0.762-0.938 2.00 × 10−3 0.068 
rs1049623 DDR1 Allelic 0.92 0.870-0.965 9.00 × 10−4 0.183 
    Codominant 0.86 0.765-0.956 6.00 × 10−3 0.504 
rs1049633 DDR1 Allelic 0.87 0.804-0.939 3.70 × 10−4 0.038 
    Codominant 0.69 0.582-0.819 2.14 × 10−5 0.599 
rs1419881 TCF19 Allelic 0.91 0.867-0.958 2.80 × 10−4 0.069 
    Codominant 0.83 0.747-0.917 2.80 × 10−4 0.261 
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Figure 1. Workflow of the SNP selection. 
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Figure 2. Forest plots of the most significant results. 
 
 
